细胞和基因治疗在囊性纤维化肺病中的进展。
Advances in cell and gene-based therapies for cystic fibrosis lung disease.
机构信息
Department of Microbiology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa 52242, USA.
出版信息
Mol Ther. 2012 Jun;20(6):1108-15. doi: 10.1038/mt.2012.32. Epub 2012 Feb 28.
Abstract
Cystic fibrosis (CF) is a disease characterized by airway infection, inflammation, remodeling, and obstruction that gradually destroy the lungs. Direct delivery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to airway epithelia may offer advantages, as the tissue is accessible for topical delivery of vectors. Yet, physical and host immune barriers in the lung present challenges for successful gene transfer to the respiratory tract. Advances in gene transfer approaches, tissue engineering, and novel animal models are generating excitement within the CF research field. This review discusses current challenges and advancements in viral and nonviral vectors, cell-based therapies, and CF animal models.
摘要
囊性纤维化（CF）是一种以气道感染、炎症、重塑和阻塞为特征的疾病，这些逐渐破坏肺部。将囊性纤维化跨膜电导调节因子（CFTR）基因直接递送至气道上皮可能具有优势，因为组织可用于递呈载体的局部给药。然而，肺部的物理和宿主免疫屏障给呼吸道的成功基因转移带来了挑战。基因转移方法、组织工程和新型动物模型的进步在 CF 研究领域引起了兴奋。本文讨论了病毒和非病毒载体、基于细胞的疗法以及 CF 动物模型的当前挑战和进展。
相似文献
1
Advances in cell and gene-based therapies for cystic fibrosis lung disease.
Mol Ther. 2012 Jun;20(6):1108-15. doi: 10.1038/mt.2012.32. Epub 2012 Feb 28.
2
Genetic therapies for cystic fibrosis lung disease.
Hum Mol Genet. 2011 Apr 15;20(R1):R79-86. doi: 10.1093/hmg/ddr104. Epub 2011 Mar 21.
3
Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.
Hum Gene Ther. 2020 May;31(9-10):524-537. doi: 10.1089/hum.2020.013. Epub 2020 Apr 15.
4
Vector-specific complementation profiles of two independent primary defects in cystic fibrosis airways.
Hum Gene Ther. 1998 Mar 20;9(5):635-48. doi: 10.1089/hum.1998.9.5-635.
5
Cell-Based Therapeutic Approaches for Cystic Fibrosis.
Int J Mol Sci. 2020 Jul 23;21(15):5219. doi: 10.3390/ijms21155219.
6
Delivery of genes into the CF airway.
Thorax. 2014 Oct;69(10):962-4. doi: 10.1136/thoraxjnl-2014-205835. Epub 2014 Jul 11.
7
Gene and cell therapy for cystic fibrosis: from bench to bedside.
J Cyst Fibros. 2011 Jun;10 Suppl 2:S114-28. doi: 10.1016/S1569-1993(11)60017-9.
8
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Cochrane Database Syst Rev. 2007 Apr 18(2):CD005599. doi: 10.1002/14651858.CD005599.pub2.
9
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Cochrane Database Syst Rev. 2013 Nov 26(11):CD005599. doi: 10.1002/14651858.CD005599.pub4.
10
Relationships among CFTR expression, HCO3- secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies.
Proc Natl Acad Sci U S A. 2016 May 10;113(19):5382-7. doi: 10.1073/pnas.1604905113. Epub 2016 Apr 25.
引用本文的文献
1
Adenoviral Vectors for Gene Therapy of Hereditary Diseases.
Biology (Basel). 2024 Dec 16;13(12):1052. doi: 10.3390/biology13121052.
2
Transduction of Pig Small Airway Epithelial Cells and Distal Lung Progenitor Cells by AAV4.
Cells. 2021 Apr 25;10(5):1014. doi: 10.3390/cells10051014.
3
Role of extracellular vesicles in chronic lung disease.
Thorax. 2021 Oct;76(10):1047-1056. doi: 10.1136/thoraxjnl-2020-216370. Epub 2021 Mar 12.
4
Intratracheal aerosolization of viral vectors to newborn pig airways.
Biotechniques. 2020 May;68(5):235-239. doi: 10.2144/btn-2019-0150. Epub 2020 Mar 6.
5
Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies.
Polymers (Basel). 2018 Apr 15;10(4):444. doi: 10.3390/polym10040444.
6
Magnetofection Enhances Lentiviral-Mediated Transduction of Airway Epithelial Cells through Extracellular and Cellular Barriers.
Genes (Basel). 2016 Nov 23;7(11):103. doi: 10.3390/genes7110103.
7
Cystic fibrosis: a clinical view.
Cell Mol Life Sci. 2017 Jan;74(1):129-140. doi: 10.1007/s00018-016-2393-9. Epub 2016 Oct 5.
8
Barriers to inhaled gene therapy of obstructive lung diseases: A review.
J Control Release. 2016 Oct 28;240:465-488. doi: 10.1016/j.jconrel.2016.05.031. Epub 2016 May 16.
9
RNA Interference in the Age of CRISPR: Will CRISPR Interfere with RNAi?
Int J Mol Sci. 2016 Feb 26;17(3):291. doi: 10.3390/ijms17030291.
10
Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction.
F1000Prime Rep. 2015 May 27;7:64. doi: 10.12703/P7-64. eCollection 2015.
本文引用的文献
1
Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study.
Lancet. 2011 Dec 10;378(9808):1997-2004. doi: 10.1016/S0140-6736(11)61715-7. Epub 2011 Nov 24.
2
N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.
Mol Ther. 2011 Nov;19(11):1981-9. doi: 10.1038/mt.2011.160. Epub 2011 Aug 9.
3
The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice.
J Clin Invest. 2011 Jun;121(6):2427-35. doi: 10.1172/JCI57367. Epub 2011 May 16.
4
Evidence for human lung stem cells.
N Engl J Med. 2011 May 12;364(19):1795-806. doi: 10.1056/NEJMoa1101324.
5
Comparative biology of cystic fibrosis animal models.
Methods Mol Biol. 2011;742:311-34. doi: 10.1007/978-1-61779-120-8_19.
6
Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
Gene Ther. 2011 Oct;18(10):996-1005. doi: 10.1038/gt.2011.55. Epub 2011 Apr 21.
7
Anionic liposomes enhance and prolong adenovirus-mediated gene expression in airway epithelia in vitro and in vivo.
Mol Pharm. 2011 Jun 6;8(3):673-82. doi: 10.1021/mp100404q. Epub 2011 Apr 29.
8
Current status and future directions of gene and cell therapy for cystic fibrosis.
BioDrugs. 2011 Apr 1;25(2):77-88. doi: 10.2165/11586960-000000000-00000.
9
The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs.
Sci Transl Med. 2011 Mar 16;3(74):74ra24. doi: 10.1126/scitranslmed.3001868.
10
Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection.
Blood. 2011 May 19;117(20):5332-9. doi: 10.1182/blood-2010-09-306761. Epub 2011 Mar 14.
Zotero 插件